Amanzada, Ahmad

[["dc.bibliographiccitation.artnumber","260"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Research Notes"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Goralzcyk, Armin D."],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Mihm, Sabine"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:41:45Z"],["dc.date.available","2019-07-09T11:41:45Z"],["dc.date.issued","2015"],["dc.description.abstract","Background Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 appears to be involved in hepatitis C virus replication. Methods We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate analysis were used in the statistical analysis. Results Baseline serum vitamin B12 levels were found to be positively associated with serum transaminase activities (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable interferon-λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with rapid virological response (p = 0.001). Patients with baseline serum vitamin B12 levels below a cut-off value of 570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3–41.9, p < 0.0001] compared to patients above the cut-off value. By combining serum vitamin B12 levels and IFNL3/IFNL4 rs12979860 genotypes, patients with baseline serum vitamin B12 levels below the cut-off value of 570 ng/L and IFNL3/IFNL4 rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9–293, p < 0.0001) compared to patients above the cut-off value and non-CC-genotypes. Conclusion Our data suggest baseline serum vitamin B12 levels as useful noninvasive marker for characterizing CHC patients. They might further help to identify responders to a standard treatment."],["dc.identifier.doi","10.1186/s13104-015-1248-z"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12298"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58502"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","227"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Digestion"],["dc.bibliographiccitation.lastpage","235"],["dc.bibliographiccitation.volume","102"],["dc.contributor.affiliation","Bremer, Sebastian C.B.; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Conradi, Lena-Christin; \r\n bClinic for General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Mechie, Nicolae-Catalin; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Amanzada, Ahmad; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Mavropoulou, Eirini; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Kitz, Julia; \r\n cInstitute of Pathology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Ghadimi, Michael; \r\n bClinic for General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Ellenrieder, Volker; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Ströbel, Philipp; \r\n cInstitute of Pathology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Hessmann, Elisabeth; \r\n aClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Gaedcke, Jochen; \r\n bClinic for General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.affiliation","Bohnenberger, Hanibal; \r\n cInstitute of Pathology, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Hessmann, Elisabeth"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2021-04-26T11:54:07Z"],["dc.date.available","2021-04-26T11:54:07Z"],["dc.date.issued","2021"],["dc.date.updated","2022-03-21T21:17:53Z"],["dc.description.abstract","Colorectal cancer (CRC) is the leading gastrointestinal malignancy. The development from premalignant intraepithelial lesions leading to invasive cancer is paradigmatic for the stepwise carcinogenesis of epithelial cancers, but the knowledge of the underlying mechanism of carcinogenesis and progression of CRC is still incomplete. The understanding of epigenetic mechanisms of carcinogenesis has led to new therapeutic approaches during the last years. Enhancer of zeste homolog 2 (EZH2) is one central epigenetic silencer of the polycomb repressor complex 2 (PRC2) that is already in clinical use as a novel drug target and is associated with poorer prognosis in several cancer entities."],["dc.identifier","31694013"],["dc.identifier.doi","10.1159/000504093"],["dc.identifier.pmid","31694013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/84358"],["dc.language.iso","en"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9867"],["dc.relation.issn","0012-2823"],["dc.relation.issn","1421-9867"],["dc.rights.uri","https://www.karger.com/Services/SiteLicenses"],["dc.title","Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","759"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","World Journal of Hepatology"],["dc.bibliographiccitation.lastpage","765"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Röver, Christian"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:40:35Z"],["dc.date.available","2019-07-09T11:40:35Z"],["dc.date.issued","2014"],["dc.description.abstract","AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-α (Peg-INF-α) based triple-therapy. METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in order to investigate determinants of SVR. RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34, 95%CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, 95%CI: 1.43-2.48) receiving triple-therapy. The line of therapy (treatment-naïve or -experienced for Peg-INF-α) did not affect the predictive value of IL-28B (P = 0.1). IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively. The odds for CC genotype patients treated with Faldaprevir cannot be quantified, as only a single study with a 100% SVR rate was available. CONCLUSION: IL-28B-SNP predicts the outcome for chronic HCV genotype-1 patients receiving protease inhibitor-based triple-therapy. The predictive value varies between the different protease inhibitors."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2014"],["dc.identifier.doi","10.4254/wjh.v6.i10.759"],["dc.identifier.fs","608037"],["dc.identifier.pmid","25349647"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11082"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58209"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.issn","1948-5182"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0233811"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Knoop, Richard"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2021-04-14T08:25:13Z"],["dc.date.available","2021-04-14T08:25:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0233811"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81557"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e25111"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Burmester, Merle"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2021-06-01T10:47:00Z"],["dc.date.available","2021-06-01T10:47:00Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1097/MD.0000000000025111"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85446"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0223893"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bathe, Anna Luisa"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2020-12-10T18:42:11Z"],["dc.date.available","2020-12-10T18:42:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1371/journal.pone.0223893"],["dc.identifier.eissn","1932-6203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16609"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77836"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e000258"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open Gastroenterology"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ternes, Kristin"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Bremer, Sebastian Christopher Benjamin"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Background Concurrent cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) and after haematopoietic stem cell transplantation (HSCT) is an important clinical entity associated with high rates of morbidity and mortality. Methods A retrospective study of 47 patients with IBD and 61 HSCT patients was performed regarding the evaluation of diagnostic accuracy of applied methods, predictors, risk factors for CMV disease manifestation, the proportion of patients with antiviral treatment and disease outcome. Results The sensitivity of quantitative PCR (qPCR) with a cut-off value of >250 copies/mg for CMV colitis in patients with IBD and HSCT patients was 79% and 92%, respectively. Predictors for CMV colitis in the IBD cohort were anaemia and the presence of endoscopic ulcers. Glucocorticoids, calcineurin inhibitors and >2 concurrent lines of treatment with immunosuppressive drugs could be identified as risk factors for CMV colitis in the IBD cohort with an OR of 7.1 (95% CI 1.7 to 29.9), 21.3 (95% CI 2.4 to 188.7) and 13.4 (95% CI 3.2 to 56.1), respectively. Predictors and risk factors for CMV gastroenteritis in the HSCT cohort was the presence of endoscopic ulcers (OR 18.6, 95% CI 3.3 to 103.7) and >2 concurrent lines of treatment with immunosuppressive drugs. Antiviral therapy was administered in 70% of patients with IBD and 77% of HSCT patients with CMV disease. 71% of antiviraltreated patients with IBD showed an improvement of their disease activity and 14% underwent colectomy. The mortality rate of HSCT patients was 21% irrespective of their CMV status. Conclusions In addition to the implementation of histological methods, qPCR may be performed in patients with suspected high-risk IBD and HSCT patients for CMV colitis. Independent validations of these results in further prospective studies are needed."],["dc.identifier.doi","10.1136/bmjgast-2018-000258"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15876"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59717"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e15172"],["dc.bibliographiccitation.firstpage","e15172"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2020-12-10T18:20:07Z"],["dc.date.available","2020-12-10T18:20:07Z"],["dc.date.issued","2019"],["dc.description.abstract","The incidence of inflammatory bowel disease (IBD) is increasing and the pathogenesis is still not completely understood. Micronutrients like vitamin D [25 (OH)D] and zinc play an important role in enzyme activities and the immune system. As the 25 (OH)D-receptor has been shown to be downregulated in patients with IBD, 25 (OH)D may emerge as a predictive marker for disease improvement. Studies on relationship of both micronutrients in IBD patients are lacking.We retrospectively evaluated serum levels of 25(OH)D and zinc together with baseline characteristics of 232 IBD patients. Uni- and multivariate analyses were performed for association between serum levels of 25(OH)D and zinc with clinical and deep remission (CR and DR).155 Crohn's disease (CD) and 77 ulcerative colitis (UC) patients were included. 54% (n = 125) and 6% (n = 14) of IBD patients showed deficient serum 25(OH)D levels below 20 ng/mL and zinc levels below 7 μmol/L. Serum 25(OH)D levels were significantly higher in IBD patients with CR (P = .02) and DR (P < .001) but not serum zinc levels, respectively. Serum 25(OH)D levels (P = .008), anti-tumor-necrosis-factor-α-trough-concentration (anti-TNF-α-TC) (P = .02) and CRP level (P = .02) were independently associated with CR in CD patients. Serum 25(OH)D threshold of 19 ng/mL discriminated CD patients with or without CR, having an area under the receiver operating curve analysis (AUROC) of 0.77 [95%-confidence interval (CI): 0.68-0.85]. In multivariate analysis serum 25(OH)D levels (P = .04) and anti-TNF-α-TC (P = .04) were associated with DR in CD patients. Serum 25(OH)D threshold of 26 ng/mL discriminated CD patients with or without DR, having an AUROC of 0.75 (95%-CI: 0.68-0.83).Serum 25(OH)D (P = .04) and fecal calprotectin levels (P = .04) were independently correlated with CR in UC patients. Serum 25(OH)D threshold of 32 ng/mL discriminated UC patients in CR with an AUROC of 0.83 (95%-CI: 0.71-0.95). Zinc levels did not correlate with disease activity status in CD or UC patients either.In conclusion, beside CRP and fecal calprotectin, serum 25(OH)D levels, but not serum zinc levels, may be an additional useful and noninvasive marker for characterizing different disease activity status of IBD patients. Measurement of serum 25(OH)D in IBD patients may be warranted. 25(OH)D supplementation in deficient IBD patients is recommended."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000015172"],["dc.identifier.eissn","1536-5964"],["dc.identifier.issn","0025-7974"],["dc.identifier.pmid","30985701"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Serum vitamin D but not zinc levels are associated with different disease activity status in patients with inflammatory bowel disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","574"],["dc.bibliographiccitation.journal","Case Reports in Gastroenterology"],["dc.bibliographiccitation.lastpage","580"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Schoehl, Johanna"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Schwoerer, Harald"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Buck, Cordula"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:42:57Z"],["dc.date.available","2019-07-09T11:42:57Z"],["dc.date.issued","2016"],["dc.description.abstract","The occurrence of a noninfectious interstitial lung disease is a rare but life-threatening side effect of infliximab, an antitumor necrosis factor alpha antibody. The following case report of a patient with Crohn disease shows an extremely dramatic progression to a severe acute respiratory distress syndrome."],["dc.identifier.doi","10.1159/000450676"],["dc.identifier.pmid","27920644"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58794"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1662-0631"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]